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Abstract: Polylactide-glycolide (PLGA) nanoparticles have been developed as pulmonary drug delivery carriers. To investigate their 
behavior, small- (d50 = 74 nm) and large-sized (d50 = 250 nm) FITC-conjugated PLGA nanoparticles were intratracheally adminis-
tered to rats and were traced for 5, 30 and 60 minutes and 24 hours after administration (HAT). Immunohistochemically, a, FITC-
positive reaction was observed in type-I alveolar epithelial cells (type-I AEC), endothelial cells and alveolar macrophages in the lungs 
from 5 minutes after treatment (MAT) to 24 HAT in both nanoparticle groups. In the kidneys, a positive reaction was observed in 
proximal tubular epithelial cells at 30 MAT; the reaction peaked at 60 MAT and was reduced at 24 HAT, while no positive reaction 
was seen in other sites. Ultrascructurally, the number of membrane-bound vesicles, which were approximately 70 nm in size and hard 
to distinguish from pinocytic vesicles, apparently increased in type-I AEC and endothelial cells at 5 MAT in the small-sized group, 
in comparison with the control group receiving physiological saline. The number of vesicles in the large-sized group was almost same 
as that in the control group. On the other hand, in both nanoparticle groups, lysosomes filled with nanoparticles appeared in alveolar 
macrophages from 30 MAT to 24 HAT. These results indicate that PLGA nanoparticles might be quickly transferred from the alveolar 
space to the blood vessel via type-I alveolar epithelial cells and excreted into urine, and that there is a threshold for particle size, less 
than approximately 70 nm in diameter, with regard to absorption through the alveolar wall. (DOI: 10.1293/tox.25.19; J Toxicol Pathol 
2012; 25: 19–26)
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Introduction
In preclinical studies, liposomes1–6, microparticles and 
nanoparticles using bioabsorbable polymers7–9 have been 
developed as drug delivery carriers for pulmonary adminis-
tration of proteins, peptides and nucleic acids. The authors 
have developed composite particles containing an excipient 
and drug encapsulated in bioabsorbable polymeric nanopar-
ticles for dry powder inhalation to treat lung and systemic 
diseases with improved pharmacological effects10. In in-vi-
vo studies with beagles, it was found that the pharmacologi-
cal effect of administering insulin encapsulated in PLGA 
nanoparticles after a single inhalation was 3.5 times higher 
than that of applying intravenous administration of insulin 
solution and that the blood glucose level was decreased af-
ter the single dosage within a matter of hours and returned 
to a normal value 24 hours later11. In a rat model of mono-
crotaline-induced pulmonary arterial hypertension (PAH), 
a single intratracheal instillation of NFκB decoy encapsu-
lated in PLGA nanoparticles delivered the nanoparticles to 
lung, which mediated NFκB decoy and prevented monocro-
taline-induced NFκB activation. It played a primary role in 
the pathogenesis of PAH and attenuated the development of 
PAH to improve the survival rates of rats12.
These pharmacological effects were the results of 
improved cell adherence, better cellular uptake, and sus-
tained release of encapsulating drug due to the use of PLGA 
nanoparticles. Thus, the nanoparticles could be applied as 
drug delivery carriers for pulmonary administration. How-
ever, the behavior of PLGA nanoparticles after pulmonary 
drug administration has not been fully examined so far. 
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Also, it is very important to evaluate the tissue pathology 
and histology to insure the safety of using PLGA nanopar-
ticles in the early stages of studies before clinical trials. Our 
previous report applied the pathological and histological ex-
aminations of rat tissues to evaluate the dynamic state of a 
single dose of a drug encapsulated in PLGA nanoparticles 
within 24 hours of administration. After intratracheal in-
stillation of FITC-encapsulated PLGA nanoparticles, FITC 
was found to be absorbed immediately through type-I al-
veolar epithelial cells13.
However, the dynamic state of the PLGA nanoparti-
cles themselves could not be evaluated because the previ-
ous method could not determine whether the detected FITC 
was released from the encapsulated PLGA nanoparticles or 
in the encapsulated PLGA nanoparticles. Therefore, FITC 
-conjugated PLGA nanoparticles were used in this study. 
After they were administered intratracheally to rats, the 
FITC distributions in several rat tissues stained immunohis-
tochemically were investigated by histological and patho-
logical examinations because this method enables evalua-
tion the distribution of PLGA nanoparticles simply and with 
high sensitivity, and the intracellular distribution of PLGA 
nanoparticles was evaluated with an electron microscope.
Materials and Methods
Materials
PLGA copolymer with a 75:25 ratio of lactic acid to 
glycolic acid and an average molecular weight of 20,000 
(PLGA7520) from Wako Pure Chemical Industries (Osa-
ka,  Japan)  and  fluorescein-4-isothiocyanate  (FITC)  from 
Dojindo Laboratories (Kumamoto, Japan) were used in this 
study. FITC-conjugated PLGA (FITC-PLGA) was prepared 
by the method of Kim S.H. et al.14 using the above materials. 
Polyvinyl alcohol (PVA EG05, Nippon Synthetic Chemical 
Industry Co., Osaka, Japan) was used as the dispersant for 
the production of nanoparticles.
Preparation of FITC-PLGA nanoparticles
Three kinds of FITC-PLGA nanoparticles with differ-
ent particles sizes were prepared by a previously reported 
emulsion solvent diffusion method in water15,16 respectively. 
First, 0.5 g of FITC-PLGA was dissolved in solution con-
taining acetone and ethanol. Then, the organic solution was 
slowly poured into PVA aqueous solution stirred at 400 rpm 
and 40 °C to form a nanoparticle suspension. After vacuum 
evaporation of organic solvent, the suspension of FITC-
PLGA nanoparticles was lyophilized to produce dry pow-
der.
Physical evaluation of FITC-PLGA nanoparticles
The shape of freeze-dried nanoparticles was analyzed 
by field emission scanning electron microscopy (FE-SEM; 
JSM-7401F, JEOL Ltd., Tokyo, Japan). The number-equiv-
alent mean particle diameter of the nanoparticles was de-
termined from a cumulative distribution curve consisting 
300 circle-equivalent diameters of particles obtained by 
FE-SEM image analysis with Image J (developed by the 
National Institutes of Health). The particle diameter is also 
known as the Heywood diameter. The surface charge of the 
nanoparticles dispersed in distilled water was measured by 
cataphoresis (Zetasizer Nano Z, Malvern, England).
Measurement of in vitro FITC release kinetics
The FITC elution ratio of FITC-PLGA nanoparticles 
was calculated by dividing the quantity of FITC released 
from the nanoparticles by the quantity of FITC included in 
the nanoparticles. The quantity of FITC released from the 
nanoparticles was obtained as follows: 100  mg of FITC-
PLGA nanoparticles was dispersed in 10 mL of distilled 
water. Then, the solution was transferred to a dialysis mem-
brane (inner phase) (Spectra/por®, 3.5 kDa molecular cut-
off: 3.5 kDa, Spectrum Laboratories, Inc., Rancho Domin-
guez, CA, USA). After that, the membrane was dipped into 
500  mL of distilled water (outer phase). After 24 hours, 
1 mL of solution in the outer phase was sampled, and its 
FITC  content  was  determined  by  fluorophotometer  (FP-
6500, JASCO Corporation, Tokyo, Japan) at the excitation 
and emission wavelengths of 490 and 520 nm, respectively.
The quantity of FITC included in the nanoparticles was 
measured as follows: 20 mg of FITC-PLGA nanoparticles 
5 mL of acetonitrile. Then, 50 mL of distilled water was 
added to separate out the PLGA. After that, the suspension 
was filtrated through a hydrophilic PTFE membrane filter 
(pore size: 0.2 μm, Advantec Toyo Kaisha, Ltd., Tokyo, Ja-
pan), and the FITC content in the filtrate was determined by 
the fluorophotometer under the conditions described above.
Animals
A total of 36 male Sprague-Dawley rats aged 5 weeks 
were purchased from Charles River Laboratories Japan, Inc. 
(Kanagawa, Japan), and were housed individually in wire 
cages in an environmentally controlled room (temperature 
of 23 ± 3°C, relative humidity of 55 ± 20%, ventilation rate 
of 10–15 times per hour and a 12-h/12-h light/dark cycle), 
fed a commercial diet (CRF-1; Oriental Yeast Co., Ltd., To-
kyo, Japan) and tap water ad libitum and used in the this 
experiment at 14 weeks of age. Animal experiments were 
conducted in accordance with the Guide for Animal Experi-
mentation of Bozo Research Center Inc.
Experimental design
Animals were divided into the control group and small- 
and large-sized FITC-PLGA nanoparticle groups, which 
contained the same number of animals, and were intratra-
cheally administered a single dose of 0.5 mL of saline sus-
pension containing 40 mg of FITC-PLGA nanoparticles in 
the nanoparticle groups and physiological saline in the con-
trol group, according to the method described previously17. 
Three rats per group were sacrificed under ether anesthesia 
at 5, 30 and 60 min and 24 hours after treatment (HAT), and 
the lungs, livers, kidneys, brains, spleens and pancreases 
were removed for further analyses.Hara, Tsujimoto, Huang et al. 21
Immunohistochemical evaluation
Each organ was preserved in neutral buffered formalin 
fixative, embedded in paraffin and sectioned. After deparaf-
finization, the sections were reacted immunohistochemical-
ly with anti-FITC monoclonal antibody (1:1000, American 
Research Products, Waltham, MA, USA) using Envision 
polymer reagent (DakoCytomation, Carpinteria, CA, USA) 
and visualized with 3,3′-diaminobenzidine tetrahydrochlo-
ride and counterstained with hematoxylin.
Ultrastructural evaluation of the lungs
Tissue samples were taken from three different areas in 
the left lobe that appeared yellow in color in the FITC-PLGA 
nanoparticle groups and three randomly selected areas in 
the control group. The samples were fixed with a mixture 
of 0.5% glutaraldehyde and 1.5% paraformaldehyde under 
deaeration by a vacuum pump (RP 75, JEOL Ltd., Tokyo, 
Japan) at 100 L/min for 5 min, postfixed with 1% osmium 
tetroxide and embedded in epoxy resin. Ultrathin sections 
were double-stained with uranyl acetate and lead citrate and 
observed under a transmission electron microscope (JEM-
100CX II, Nippon Denshi, Tokyo, Japan).
Results and Discussion
Characterization of FITC-PLGA nanoparticles
Two kinds of FITC-PLGA nanoparticles were pre-
pared, smaller particles (mean diameter 74 nm) and larger 
particles (mean diameter 250  nm). The particle size dis-
tribution is shown in Fig. 1, and an FE-SEM photograph 
of each particle, which exhibited the same features as the 
FITC-loaded PLGA nanoparticles in our previous report13, 
is shown in Fig. 2. The surface charge of these particles was 
about −17 mV. The FITC elution ratio for the small-sized 
FITC-PLGA nanoparticles was found to be 1.9%. Therefore, 
FITC detection could be used as the marker to trace the dy-
namic state of PLGA nanoparticles.
Necropsy findings
No  abnormal  findings  were  observed  in  the  control 
group. In both the small- and large-sized FITC-PLGA 
nanoparticle groups, the whole lungs turned yellow in color, 
from the main bronchi to the periphery, and the color re-
mained until 24 HAT.
Immunohistochemical evaluation of FITC-PLGA 
nanoparticles
In the lungs, no immunopositive reaction for FITC 
was observed in the control group. As shown in the Fig. 3, 
a FITC-positive reaction was found in the alveolar wall at 5 
minutes after treatment (MAT) in the small-sized nanopar-
ticle group. The positive reaction was also detected at 24 
HAT (Fig. 3d). This result suggests that uptake of PLGA 
nanoparticles might be rapid and that the nanoparticles 
might remain at least until 24 HAT. In addition, a FITC-
positive reaction was observed in the alveolar macrophages 
from 5 MAT to 24 HAT. This indicates that the PLGA 
nanoparticles might be recognized as foreign substances by 
alveolar macrophages.
Fig. 1.  Particle size distribution of FITC-conjugated PLGA nanopar-
ticles in water.
Fig. 2.  Scanning electron microscope photograph of the small-sized (a) and large-sized FITC-PLGA nanoparticles (b).Behavior of PLGA-nanoparticles in Rat Lungs 22
In the kidneys, no immunopositive reaction for FITC 
was observed in the control group. As shown in the Fig. 4, a 
FITC-positive reaction firstly appeared in proximal tubules 
at 30 MAT and was detected in proximal tubules until 24 
HAT, whereas no distinct positive reaction for FITC was 
observed in the glomeruli. Taken together with the minimal 
elution of FITC from the PLGA-nanoparticles as mentioned 
above, it is considered that the FITC-PLGA nanoparticles 
are absorbed in the lungs, transferred to the blood circula-
tion and finally excreted into urine; the detailed excretion 
pathway will be determined by further studies. It may also 
be suggested that intractable glomerulonephritis is unlikely 
to be contracted by administering FITC-PLGA nanopar-
ticles.
As for the liver, which plays an important role in me-
tabolism of foreign substances, little FITC was found in 
the portal vein area, central vein area or Kupffer cells at 24 
HAT. Also, little FITC was found in the spleen, pancreas or 
brain.
Ultrastructural evaluation of FITC-PLGA nanopar-
ticles in the lungs
In the control group, pinocytic vesicles, which were 
approximately 70 nm in diameter, were observed in type-I 
Fig. 3.  Immunohistochemistry for FITC in the lungs. Sections from the small-sized FITC-PLGA nanoparticle group at 5 
minutes (a), 30 minutes (b), 60 minutes (c) and 24 hours (d) and from the control group at 5 minutes (e) and 24 hours 
(f). AW: alveolar wall, ASp: alveolar space, AM: alveolar macrophage. Bars = 10 μm.Hara, Tsujimoto, Huang et al. 23
alveolar epithelial cells and endothelial cells in the alveo-
lar wall (Fig. 5a). Although similar vesicles were observed 
in the nanoparticle groups, the number, particular in type-I 
alveolar epithelial cells, was greatly increased in the small-
sized nanoparticle group at 5 MAT to 24 HAT (Fig. 5b, c, 
d), while the number in the large-sized group was compa-
rable to that in the control group. The nanoparticles present 
in alveolar spaces were characterized by an electron lucent 
(like they were empty), round body bounded by a single thin 
membranous substance (Fig. 6). This feature was quite sim-
ilar to that of pinocytic vesicles in type-I alveolar epithelial 
cells and endothelial cells when the diameter was around 
70 nm. Therefore, nanoparticles could not be definitively 
distinguished from pinocytic vesicles when they were pres-
ent in cytoplasm; however, it may be reasonable to consider 
that the nanoparticles approximately 70 nm in size coexist-
ed with pinocytic vesicles. Similar vesicles could not be de-
tected in type-II alveolar epithelial cells and the interstitium 
of the alveolar wall. These results indicate that uptake of 
the nanoparticles injected into the lungs by type-I alveolar 
epithelial cells and transfer to the blood stream via endothe-
lial cells might occur quickly and that there is a threshold 
for particle size, less than 70 nm in diameter, with regard to 
absorption through the alveolar wall.
On the other hand, alveolar macrophages that con-
tained secondary lysosomes with many nanoparticles, 
ranging from 50 to 500 nm, were observed in the nanopar-
ticle groups (Fig. 7) at 5 MAT and later. This finding sug-
gests that uptake of nanoparticles by not only type-I alveo-
lar epithelial cells but also alveolar macrophages was quick 
and that larger-sized and agglomerating nanoparticles are 
likely to be captured by phagocytosis by alveolar macro-
phages.
In the present experiment, we provide not only funda-
mental information but also a clue for elucidating the ab-
sorption pathway of nanoparticles in lung tissue. However, 
to clarify the uptake mechanism, absorption rate and quanti-
ty rate of these particles, sufficient data need to be collected 
in further experiments.
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Fig. 4.  Immunohistochemistry for FITC in the kidneys. Sections from the small-sized FITC-PLGA nanoparticle group at 
5 minutes (a), 30 minutes (b), 60 minutes (c) and 24 hours (d). PCT: proximal convoluted tubule. Bars = 50 μm.Behavior of PLGA-nanoparticles in Rat Lungs 24
Fig. 6.  Representative transmission electron microphotographs of intra-alveolar nanoparticles from the small-sized (a) and large-sized 
FITC-PLGA nanoparticle groups (b) at 30 minutes after treatment. Bars = 500 nm.
Fig. 5.  Representative transmission electron microphotographs of vesicles (arrowheads) in the lungs from the control (a) and the small-
sized FITC-PLGA nanoparticle groups at 5 minutes (b), 30 minutes (c), and 60 minutes (d) after treatment (inserts: higher 
magnification of the vesicles). AEp1: type-I alveolar epithelial cell; ASp: alveolar space; BM: basement membrane; BV: blood 
vessel; ET: endothelial cell. Bars = 500 nm.Hara, Tsujimoto, Huang et al. 25
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